Scholar Rock Holding Corp (NASDAQ: SRRK)

$47.40 ▲ +0.48 (+1.01%)

As of Jun 18, 2026 04:00 PM

Sector: Healthcare Industry: Biotechnology CIK: 0001727196

Market Cap 6.03 Bn

P/E -13.70

Div. Yield 0.00

Total Debt (Qtr) 196.61 Mn

Add ratio to table...

About

Scholar Rock Holding Corp is a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy and additional rare severe and debilitating neuromuscular diseases. The company focuses on the biology of the transforming growth factor beta superfamily and has built a proprietary platform that enables the discovery of monoclonal antibodies which bind the latent precursor forms of growth factors. By preventing activation of these molecules in the disease microenvironment Scholar Rock aims to increase...

Scholar Rock Holding Corp is a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy and additional rare severe and debilitating neuromuscular diseases. The company focuses on the biology of the transforming growth factor beta superfamily and has built a proprietary platform that enables the discovery of monoclonal antibodies which bind the latent precursor forms of growth factors. By preventing activation of these molecules in the disease microenvironment Scholar Rock aims to increase muscle mass and function while preserving normal physiological processes. Its lead product candidate apitegromab is an investigational fully human monoclonal antibody administered intravenously that selectively binds pro and latent myostatin to inhibit its catabolic activity. Scholar Rock is also developing a subcutaneous formulation of apitegromab to provide patients with a convenient self administered option. A second myostatin inhibitor SRK 439 is being evaluated as a subcutaneous agent with high affinity and selectivity for myostatin over related growth factors. Beyond myostatin the company leverages its platform to create inhibitors of latent TGFβ1 for oncology indications such as SRK 181 for tumors resistant to checkpoint blockade. Additional programs target fibrosis through SRK 373 and iron restricted anemia through SRK 256. The company’s scientific foundation rests on the pioneering work of its founders Dr Timothy A Springer and Dr Leonard I Zon whose insights into growth factor activation underlie the entire approach.

Scholar Rock Holding Corp does not yet generate revenue from the sale of approved products because its product candidates remain in clinical development. The company’s current revenue stems from collaboration agreements that provide upfront payments milestone payments and potential future royalties. In December 2018 Scholar Rock entered into a three year collaboration with Gilead to discover and develop therapeutics that target TGFβ driven signaling receiving an upfront cash payment of fifty million dollars and an equity investment of thirty million dollars. Under the same agreement the company achieved a preclinical milestone in December 2019 triggering an additional twenty five million dollar payment. Scholar Rock also maintains an amended and restated collaboration with Adimab LLC under which it pays a technology access fee and is obligated to make technical milestone payments and option exercise fees upon successful development of antibodies. The Adimab agreement further requires royalty payments on net sales of any product that emerges from the collaboration. Looking ahead Scholar Rock anticipates that upon regulatory approval of apitegromab or other candidates it will begin to record product sales revenue and will earn royalties from out licensed assets. Until such time all financial inflow is derived from these partnership arrangements.

Scholar Rock Holding Corp differentiates itself in the biotechnology sector by focusing on the inhibition of latent growth factors rather than their active forms. This strategy provides a mechanistic advantage because latent forms exhibit structural diversity that allows for selective targeting of individual family members such as myostatin without affecting closely related proteins like GDF11 or activins. In the spinal muscular atrophy arena the company competes with approved SMN directed therapies including nusinersen risdiplam and onasemnogene abeparvovec and with other myostatin antagonists being investigated by Roche Biogen and NMD Pharma. Scholar Rock believes its proprietary antibody apitegromab offers a first in human demonstration of clinically meaningful motor benefit in patients already receiving background SMN therapy. For its SRC 181 program the company faces competition from firms developing TGFβ pathway inhibitors for use alongside checkpoint inhibitors such as AbbVie Roche Bicara Therapeutics Novartis Bristol Myers Squibb and Merck KGaA. The company’s intellectual property portfolio is extensive with multiple patent families covering its platform product candidates and therapeutic methods. As of the end of 2025 Scholar Rock held thirty two pending or granted patent families with core platform patents projected to expire in 2034 and myostatin related patents projected to expire between 2035 and 2043. This long lived patent estate is intended to protect its innovations and to provide freedom to operate as its candidates advance toward commercialization. Furthermore the company’s deep expertise in growth factor biology and its internal antibody discovery capabilities reinforce its competitive stance.

Scholar Rock Holding Corp serves individuals living with rare and severe neuromuscular diseases that are characterized by muscle atrophy and weakness. The primary patient populations include children and adults with spinal muscular atrophy who are receiving baseline SMN directed therapy patients with facioscapulohumeral muscular dystrophy and individuals with other neuromuscular conditions where loss of muscle mass contributes to disease progression. In oncology the company targets patients with locally advanced or metastatic solid tumors that have become resistant to immune checkpoint inhibition and who may benefit from TGFβ1 blockade to restore antitumor immunity. In the fibrosis area Scholar Rock aims to treat patients with organ specific scarring such as chronic kidney disease lung fibrosis or liver cirrhosis where excess extracellular matrix drives morbidity. For iron restricted anemia the company focuses on patients with conditions such as chronic kidney disease inflammatory bowel disease or cancer where elevated hepcidin limits iron availability. While the filing does not list specific named customers the end users of Scholar Rock’s therapies are patients who receive care in hospitals specialty infusion centers and neurology or oncology clinics. Healthcare providers including neurologists oncologists pulmonologists and hepatologists are involved in prescribing and administering the treatments. Payers such as private insurers and government programs determine coverage and reimbursement. Collaboration partners such as Gilead and Adimab support research and development but are not considered customers in the commercial sense.

Investment thesis

Bull case

Scholar Rock’s apitegromab is positioned to address a critical unmet need in the SMA market, a population of roughly 35,000 patients worldwide who already receive SMN‑targeted therapies that protect motor neurons but leave skeletal muscle weakness unaddressed. The Phase 3 SAPPHIRE trial demonstrated statistically significant and clinically meaningful improvements in motor function, providing a strong efficacy foundation that has not yet been replicated by any competitor. Even with the recent CRL related to a third‑party fill‑finish facility, the FDA’s letter explicitly cited no issues with the drug’s safety or efficacy data, implying that the core product remains robust and that regulatory acceptance should be attainable once manufacturing remediation is complete. This unique mechanism, coupled with orphan and rare pediatric disease designations, creates a pricing and reimbursement environment that is likely to support high market share and premium pricing, potentially driving revenues into the $2 billion range by the early 2030s as analysts project.
Scholar Rock’s strategic plan for 2026 outlines a coordinated launch strategy that leverages both a second U.S. fill‑finish facility and a pre‑approved European production site, effectively mitigating the risk of a single manufacturing bottleneck. The company’s collaboration with Novo Nordisk’s Catalent Indiana, combined with its own commercial manufacturing expertise, positions it to resubmit a BLA and secure regulatory clearance within the same calendar year, assuming the remediation timeline remains within the 3‑month window cited by FDA and internal projections. A timely U.S. launch would not only capitalize on the momentum from the early 2025 Type A meeting but also provide a launch pad for subsequent indications in infants, adolescents, and potentially other neuromuscular disorders such as FSHD. By 2027, a global launch strategy that includes Germany and other European markets could capture a sizable share of the rapidly expanding obesity‑associated muscle preservation niche, especially as GLP‑1 agents become mainstream.
The company’s proprietary myostatin biology platform is not limited to apitegromab; the subcutaneous formulation of SRK‑439 offers a self‑injectable alternative that could reduce administration costs, improve patient adherence, and open new markets where weekly or monthly infusions are less feasible. Early data from a healthy‑volunteer Phase 1 study and the impending IND clearance in Q4 2025 signal a fast‑track path to clinical development, potentially providing a diversified revenue stream and a hedge against apitegromab’s single‑product risk. Moreover, the Phase 2 OPAL trial for infants under two years targets a highly vulnerable subgroup that currently has no pharmacologic options beyond gene therapy, positioning Scholar Rock to become a first‑in‑class provider in the pediatric segment and to leverage early adopter benefits. These pipeline assets suggest a sustained growth trajectory beyond the flagship product, increasing the company’s appeal to investors seeking multi‑indication exposure within the rare‑disease space.
Scholar Rock’s cash runway, standing at approximately $370 million as of September 2025 and supported by an additional $60 million in expiring warrants, comfortably covers its projected operating expenses through the end of 2027. Even with the Q3 2025 net loss of $102 million, the company’s capital structure, reinforced by a $50 million drawdown from a debt facility and a recent equity offering, provides a buffer against unforeseen delays in regulatory approvals or commercialization milestones. The management’s disciplined spending—evidenced by the incremental increases in R&D and G&A tied directly to launch readiness—demonstrates financial prudence that can withstand short‑term cash burn while preserving long‑term growth potential. This financial foundation is critical in a sector where extended timelines are common, and the company’s ability to fund operations into 2027 positions it favorably against peers who may require additional capital rounds.

Scholar Rock’s apitegromab is positioned to address a critical unmet need in the SMA market, a population of roughly 35,000 patients worldwide who already receive SMN‑targeted therapies that protect motor neurons but leave skeletal muscle weakness unaddressed. The Phase 3 SAPPHIRE trial demonstrated statistically significant and clinically meaningful improvements in motor function, providing a strong efficacy foundation that has not yet been replicated by any competitor. Even with the recent CRL related to a third‑party fill‑finish facility, the FDA’s letter explicitly cited no issues with the drug’s safety or efficacy data, implying that the core product remains robust and that regulatory acceptance should be attainable once manufacturing remediation is complete. This unique mechanism, coupled with orphan and rare pediatric disease designations, creates a pricing and reimbursement environment that is likely to support high market share and premium pricing, potentially driving revenues into the $2 billion range by the early 2030s as analysts project.
Scholar Rock’s strategic plan for 2026 outlines a coordinated launch strategy that leverages both a second U.S. fill‑finish facility and a pre‑approved European production site, effectively mitigating the risk of a single manufacturing bottleneck. The company’s collaboration with Novo Nordisk’s Catalent Indiana, combined with its own commercial manufacturing expertise, positions it to resubmit a BLA and secure regulatory clearance within the same calendar year, assuming the remediation timeline remains within the 3‑month window cited by FDA and internal projections. A timely U.S. launch would not only capitalize on the momentum from the early 2025 Type A meeting but also provide a launch pad for subsequent indications in infants, adolescents, and potentially other neuromuscular disorders such as FSHD. By 2027, a global launch strategy that includes Germany and other European markets could capture a sizable share of the rapidly expanding obesity‑associated muscle preservation niche, especially as GLP‑1 agents become mainstream.
The company’s proprietary myostatin biology platform is not limited to apitegromab; the subcutaneous formulation of SRK‑439 offers a self‑injectable alternative that could reduce administration costs, improve patient adherence, and open new markets where weekly or monthly infusions are less feasible. Early data from a healthy‑volunteer Phase 1 study and the impending IND clearance in Q4 2025 signal a fast‑track path to clinical development, potentially providing a diversified revenue stream and a hedge against apitegromab’s single‑product risk. Moreover, the Phase 2 OPAL trial for infants under two years targets a highly vulnerable subgroup that currently has no pharmacologic options beyond gene therapy, positioning Scholar Rock to become a first‑in‑class provider in the pediatric segment and to leverage early adopter benefits. These pipeline assets suggest a sustained growth trajectory beyond the flagship product, increasing the company’s appeal to investors seeking multi‑indication exposure within the rare‑disease space.
Scholar Rock’s cash runway, standing at approximately $370 million as of September 2025 and supported by an additional $60 million in expiring warrants, comfortably covers its projected operating expenses through the end of 2027. Even with the Q3 2025 net loss of $102 million, the company’s capital structure, reinforced by a $50 million drawdown from a debt facility and a recent equity offering, provides a buffer against unforeseen delays in regulatory approvals or commercialization milestones. The management’s disciplined spending—evidenced by the incremental increases in R&D and G&A tied directly to launch readiness—demonstrates financial prudence that can withstand short‑term cash burn while preserving long‑term growth potential. This financial foundation is critical in a sector where extended timelines are common, and the company’s ability to fund operations into 2027 positions it favorably against peers who may require additional capital rounds.

Bear case

The recent Complete Response Letter underscores a persistent vulnerability in Scholar Rock’s supply chain: dependence on a third‑party fill‑finish facility that has already manifested regulatory observations. While the letter cites no product‑specific concerns, the fact that the FDA’s inspection findings were not unique to apitegromab suggests systemic process issues that could recur, delaying resubmission or requiring extensive remedial action that may exceed the three‑month window projected by the company. Should these manufacturing challenges persist, the company could face extended periods without a launch, eroding the projected $2 billion revenue window and allowing competitors to gain market foothold in a niche where first‑mover advantage is critical.
Although the company has a second U.S. facility, the timeline for full commercial capacity remains uncertain; tech transfer and validation can be protracted, especially when integrating a new product line into a facility with a different regulatory history. Any hiccups here would compound the impact of the CRL, potentially pushing the U.S. launch beyond 2026 and compressing the commercial window. Moreover, the company’s European launch hinges on a pending EMA decision, which, while anticipated in mid‑2026, could be delayed by additional data requests or regulatory scrutiny, further narrowing the opportunity to capture a share of the growing obesity‑related muscle preservation market before competitors introduce alternatives.
Scholar Rock’s financial metrics, while sufficient for a 2027 runway, reveal a high burn rate that escalated from $53 million in G&A in 2024 to $83 million in 2025, largely driven by headcount increases and professional services. This sharp rise, coupled with a net loss of $102 million in Q3 2025, signals that the company is operating at a significant loss even as it ramps up commercialization. Any delay in product launch would require the company to continue subsidizing a high‑expense operation for an extended period, potentially depleting cash reserves faster than anticipated and forcing a costly capital raise that could dilute existing shareholders.
The company’s pipeline, while diversified, is still heavily reliant on the success of apitegromab; other candidates such as SRK‑439 and the FSHD program are in early stages and have no guarantee of clinical or regulatory success. Should apitegromab fail to secure timely approval, the remaining assets may not generate sufficient revenue to justify the current market valuation, especially given the high development costs associated with orphan drug programs. The risk that the company’s flagship product could face competitive pressure from emerging myostatin inhibitors or alternative muscle‑preserving strategies—such as gene therapy‑based approaches or novel biologics—intensifies the probability that market share could be eroded before the company achieves profitability.
Pricing and reimbursement represent additional unknowns that could materially impact the company’s financial outlook. While orphan drug status often facilitates premium pricing, payers are increasingly scrutinizing the cost‑effectiveness of high‑price therapies, especially in the United States where value‑based contracts are becoming the norm. If payers mandate stringent post‑approval studies or tie reimbursement to comparative effectiveness against SMN‑targeted therapies, Scholar Rock may face reduced net revenues or delayed payment streams, which would negatively affect cash flows and the company's ability to fund its expansive pipeline.

The recent Complete Response Letter underscores a persistent vulnerability in Scholar Rock’s supply chain: dependence on a third‑party fill‑finish facility that has already manifested regulatory observations. While the letter cites no product‑specific concerns, the fact that the FDA’s inspection findings were not unique to apitegromab suggests systemic process issues that could recur, delaying resubmission or requiring extensive remedial action that may exceed the three‑month window projected by the company. Should these manufacturing challenges persist, the company could face extended periods without a launch, eroding the projected $2 billion revenue window and allowing competitors to gain market foothold in a niche where first‑mover advantage is critical.
Although the company has a second U.S. facility, the timeline for full commercial capacity remains uncertain; tech transfer and validation can be protracted, especially when integrating a new product line into a facility with a different regulatory history. Any hiccups here would compound the impact of the CRL, potentially pushing the U.S. launch beyond 2026 and compressing the commercial window. Moreover, the company’s European launch hinges on a pending EMA decision, which, while anticipated in mid‑2026, could be delayed by additional data requests or regulatory scrutiny, further narrowing the opportunity to capture a share of the growing obesity‑related muscle preservation market before competitors introduce alternatives.
Scholar Rock’s financial metrics, while sufficient for a 2027 runway, reveal a high burn rate that escalated from $53 million in G&A in 2024 to $83 million in 2025, largely driven by headcount increases and professional services. This sharp rise, coupled with a net loss of $102 million in Q3 2025, signals that the company is operating at a significant loss even as it ramps up commercialization. Any delay in product launch would require the company to continue subsidizing a high‑expense operation for an extended period, potentially depleting cash reserves faster than anticipated and forcing a costly capital raise that could dilute existing shareholders.
The company’s pipeline, while diversified, is still heavily reliant on the success of apitegromab; other candidates such as SRK‑439 and the FSHD program are in early stages and have no guarantee of clinical or regulatory success. Should apitegromab fail to secure timely approval, the remaining assets may not generate sufficient revenue to justify the current market valuation, especially given the high development costs associated with orphan drug programs. The risk that the company’s flagship product could face competitive pressure from emerging myostatin inhibitors or alternative muscle‑preserving strategies—such as gene therapy‑based approaches or novel biologics—intensifies the probability that market share could be eroded before the company achieves profitability.
Pricing and reimbursement represent additional unknowns that could materially impact the company’s financial outlook. While orphan drug status often facilitates premium pricing, payers are increasingly scrutinizing the cost‑effectiveness of high‑price therapies, especially in the United States where value‑based contracts are becoming the norm. If payers mandate stringent post‑approval studies or tie reimbursement to comparative effectiveness against SMN‑targeted therapies, Scholar Rock may face reduced net revenues or delayed payment streams, which would negatively affect cash flows and the company's ability to fund its expansive pipeline.

Counterparty Name Breakdown of Revenue (2021)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ATHE	Alterity Therapeutics Ltd	925,601.88 Bn	-	50.75 Mn	-
2	BLTE	Belite Bio, Inc	58,560.00 Bn	-95.69	-	-
3	QNTM	Quantum Biopharma Ltd.	17,284.41 Bn	0.76	-	-
4	LEGN	Legend Biotech Corp	2,809.00 Bn	0.00	0.00 Mn	319.10 Mn
5	EVAX	Evaxion A/S	1,334.43 Bn	0.00	0.00 Mn	-
6	AKTX	Akari Therapeutics Plc	1,312.27 Bn	-44,753.60	-	-
7	PBM	Psyence Biomedical Ltd.	212.16 Bn	10.84	-	-
8	VRTX	Vertex Pharmaceuticals Inc / Ma	114.83 Bn	26.57	0.00 Mn	-

Research Tools

Developers

Scholar Rock Holding Corp (NASDAQ: SRRK)

About

Investment thesis

Bull case

Bear case

Counterparty Name Breakdown of Revenue (2021)

Peer comparison

Research Tools

Developers

Scholar Rock Holding Corp (NASDAQ: SRRK)

About

Investment thesis

Bull case

Bear case

Counterparty Name Breakdown of Revenue (2021)

Peer comparison

Create an account

Sign In

Reset Password